Scopia Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Scopia Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-402,800	Closed	-$23.2M	–	33
2014 Q4	$23.2M	Sell	402,800 -189,000	-32%	-$10.5M	0.43%	26
2014 Q3	$31.8M	Sell	591,800 -2,118,600	-78%	-$112M	0.65%	25
2014 Q2	$142M	Sell	2,710,400 -339,000	-11%	-$17.3M	3.66%	8
2014 Q1	$161M	Buy	3,049,400 +368,200	+14%	+$17M	5.11%	5
2013 Q4	$107M	Buy	2,681,200 +648,400	+32%	+$25.5M	3.27%	12
2013 Q3	$76.8M	Buy	2,032,800 +526,000	+35%	+$20.5M	2.29%	18
2013 Q2	$59.1M	Buy	+1,506,800	New	+$58.7M	1.65%	22

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Scopia Capital Management's TEVA Position: Q1 2015 in Review

Scopia Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2015, closing a stake of 3,333,717 shares — an estimated $192M sold.

Scopia Capital Management first reported a position in TEVA in Q2 2013 and held it in 7 quarters. The position peaked at $192M in Q4 2014. 821 funds tracked by Wall St. Rank hold TEVA as of Q1 2015.

Scopia Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Scopia Capital Management sold 3,333,717 Teva Pharmaceuticals shares in Q1 2015, an estimated $192M.
Scopia Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Scopia Capital Management's Teva Pharmaceuticals position peaked at $192M in Q4 2014.
821 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2015.

Based on Scopia Capital Management's 13F filing for Q1 2015, filed 15 May 2015.